MWNA
ADAP

Marshall Wace North America’s Adaptimmune Therapeutics ADAP Stock Holding History

Marshall Wace North America’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$304K Buy
+58,847
New +$264K ﹤0.01% 1236
2020
Q4 		– Sell
-154,655
Closed -$1.23M – 1277
2020
Q3 		$1.23M Sell
154,655
-283,232
-65% -$2.48M 0.01% 747
2020
Q2 		$4.38M Buy
+437,887
New +$2.75M 0.03% 390

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Marshall Wace North America's ADAP Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Adaptimmune Therapeutics (ADAP) in Q3 2021: 58,847 shares worth $304K. The stake represents ﹤0.01% of the portfolio and ranks #1236 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in ADAP as recently as Q3 2020.

Marshall Wace North America first reported a position in ADAP in Q2 2020 and has held it in 3 quarters since. The position peaked at $4.38M in Q2 2020. 92 funds tracked by Wall St. Rank hold ADAP as of Q3 2021.

  • Marshall Wace North America held 58,847 shares of Adaptimmune Therapeutics worth $304K as of Q3 2021.
  • Adaptimmune Therapeutics was a new Marshall Wace North America position in Q3 2021.
  • Adaptimmune Therapeutics made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1236 holding.
  • Marshall Wace North America first reported a position in Adaptimmune Therapeutics in Q2 2020 and has held it in 3 quarters since.
  • Marshall Wace North America's Adaptimmune Therapeutics position peaked at $4.38M in Q2 2020.
  • 92 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.